Experience with insulin-like growth factor I (IGF-I) treatment of growth hormone insensitivity syndrome (GHIS)

Journal of Pediatric Endocrinology and Metabolism

Volumn 12, Issue SUPPL. 1, 1999, Pages 259-266

  Ranke, M B ^a   Wollmann, H A ^a   Savage, M O ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Growth hormone insensitivity syndrome; Growth promotion; IGF I treatment; Laron syndrome

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE ANTIBODY; GROWTH HORMONE RECEPTOR; RECOMBINANT SOMATOMEDIN C;

ANTIBODY PRODUCTION; CHILD; CLINICAL FEATURE; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; GENE MUTATION; GROWTH HORMONE BLOOD LEVEL; HORMONAL THERAPY; HORMONE RESISTANCE; HUMAN; LARON SYNDROME; PATHOGENESIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADIPOSE TISSUE; BODY HEIGHT; CHILD; CLINICAL TRIALS; CRANIOFACIAL ABNORMALITIES; DRUG RESISTANCE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; SYNDROME;

EID: 0032998585     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Laron Z, Blum W, Chatelain P, Ranke M, Rosenfeld R, Savage M, Underewood L. Classification of growth hormone insensitivity syndrome [editorial]. J Pediatr 1993; 122: 241.
2. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentration of growth hormone - a new inborn error of metabolism? Isr J Med Sci 1966; 2: 152-155.
3. Amselem S, Sobrier ML, Dastot F, Duquesnoy P, Duriez B, Goossens M. Molecular basis of inherited growth hormone resistance in childhood. In: Ross RJM, Savage MO, eds. Clinical Endocrinology and Metabolism: International Practice and Research. London-Philadelphia-Sydney-Tokyo-Toronto: Baillière Tindall, 1996; 353-369.
4. Phillips JA 3rd, Hjelle BL, Seeburg PH, Zachmann M. Molecular basis for familial isolated growth hormone deficiency. Proc Natl Acad Sci USA 1981; 78: 6372-6375.
5. Laron Z, Anin S, Klipper Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258-1261.
6. Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992; 121: 641-646.
7. Backeljauw PF, Underwood LE, Miras M, Arriazu MC, Heinrich J, Ghizzoni L, Blethen S, Donaldson D, Cleveland W, Duncan V. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1996; 81: 3312-3317.
8. Clemmons DR, Underwood LE. Clinical Review 59: Uses of human insulin-like growth factor-I in clinical conditions. J Clin Endocrinol Metab 1994; 79: 4-6.
9. Laron Z, Klinger B. Laron syndrome: clinical features, molecular pathology and treatment. Horm Res 1994; 42: 198-202.
10. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab 1995; 8: 149-158.
11. Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, Rosenfeld RG. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80: 1393-1398.
12. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-633.
13. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Blum WF, Wilton P. Insulin-like growth factor I improves height in growth hormone insensitivity: two years' results. Horm Res 1995; 44: 253-264.
14. Savage MO, Blum WF, Ranke MB, Postel-Vinay MC, Cotterill AM, Hall K, Chatelain PG, Preece MA, Rosenfeld RG. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab 1993; 77: 1465-1471.
15. Ranke MB, Savage MO, Chatelain P, Preece MA, Rosenfeld RG, Wilton P. Treatment of growth hormone insensitivity syndrome (GHIS) with IGF-I: long-term results of the European multicenter study. In press.
16. Krzisnik C, Battelino T Five year treatment with IGF-I of a patient with Laron syndrome in Slovenia (a follow-up report). J Pediatr Endocrinol Metab 1997; 10: 443-447.
17. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994; 15: 369-390.
18. Laron Z, Avitzur Y, Klinger B. Insulin resistance in Laron syndrome (primary insulin-like growth factor-I (IGF-I) deficiency) and effect of IGF-I replacement therapy. J Pediatr Endocrinol Metab 1997; 10 (Suppl 1): 105-115.
19. Laron Z, Klinger B. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. Horm Res 1993; 40: 16-22.
20. Ranke MB, Guilbaud O. Growth response in prepubertal children with idiopathic growth hormone deficiency during the first two years of treatment with human growth hormone. Analysis of the Kabi Pharmacia International Growth Study. Acta Paediatr Scand 1991; Suppl 379: 109-115.
21. Gluckman PD. Growth hormone deficiency diagnosed and treated in the first 2 years of life: Evidence of the role of growth hormone in human perinatal growth. In: Ranke MB, Gunnarsson R, eds. Progress in Growth Hormone Therapy - 5 Years of KIGS. Mannheim: J&J Verlag, 1994; 88-96.
22. Clemmons DR, Thissen JP, Macs M, Ketelslegers JM, Underwood LE. Insulin-like growth factor-I (IGF-I) infusion into hypophysectomized or protein-deprived rats induces specific IGF-binding proteins in serum. Endocrinology 1989; 125: 2967-2972.
23. Gargosky SE, Wilson KF, Fielder PJ, Vaccarello MA, Guevara-Aguirre J, Diamond FB, Baxter RC, Rosenbloom AL, Rosenfeld RG. The composition and distribution of insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) in the serum of growth hormone receptor-deficient patients: effects of IGF-I therapy on IGFBP-3. J Clin Endocrinol Metab 1993; 77: 1683-1689.
24. Leonard J, Samuels M, Cotterill AM, Savage MO. Effects of recombinant insulin-like growth factor I on craniofacial morphology in growth hormone insensitivity. Acta Paediatr 1994; Suppl 399: 140-141.
25. Laron Z, Klinger B. Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998; 138: 176-180.
26. Klinger B, Anin S, Silbergeld A, Eshet R, Laron Z. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol 1998; 48: 81-87.
27. Zapf J, Schoenle E, Waldvogel M, Sand I, Froesch ER. Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem 1981; 113: 605-609.
28. Ballard FJ, Walton PE, Dunshea FE. Does IGF-I ever act through the insulin receptor? In: Baxter RC, Gluckman PD, Rosenfeld RG, eds. The Insulin-like Growth Factors and their Regulatory Proteins. Amsterdam: Excerpta Medica, 1994; 131-141.
29. Ranke MB, Wilton P. Adverse events during treatment with recombinant insulin-like growth factor I in patients with growth hormone insensitivity. Acta Paediatr 1994; Suppl 399: 143-145.
30. Vasconez O, Martinez V, Martinez AL, Hidalgo F, Diamond FB, Rosenbloom AL, Rosenfeld RG, Guevara-Aguirre J. Heart rate increases in patients with growth hormone receptor deficiency treated with insulin-like growth factor I. Acta Paediatr 1994; Suppl 399: 137-139.
31. Wollmann HA, Ranke MB. Bell's palsy after onset of insulin-like growth factor I therapy in a patient with growth hormone receptor deficiency. Acta Paediatr 1994; Suppl 399: 148-149.
32. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 1987; 317: 137-140.
33. Malozowski S, Tanner LA, Wysowski D, Fleming GA. Growth hormone, insulin-like growth factor I, and benign intracranial hypertension [letter]. N Engl J Med 1993; 329: 665-666.
34. Lordereau RI, Roger M, Chaussain JL. Transient bilateral papilloedema in a 10-year-old boy treated with recombinant insulin-like growth factor I for growth hormone receptor deficiency. Acta Paediatr 1994; Suppl 399: 152.